Newamsterdam Pharma Stock Cash And Equivalents
| NAMSW Stock | 9.06 0.63 6.50% |
NewAmsterdam Pharma fundamentals help investors to digest information that contributes to NewAmsterdam Pharma's financial success or failures. It also enables traders to predict the movement of NewAmsterdam Stock. The fundamental analysis module provides a way to measure NewAmsterdam Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to NewAmsterdam Pharma stock.
NewAmsterdam | Cash And Equivalents |
NewAmsterdam Pharma Company Cash And Equivalents Analysis
NewAmsterdam Pharma's Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
NewAmsterdam Cash And Equivalents Driver Correlations
Understanding the fundamental principles of building solid financial models for NewAmsterdam Pharma is extremely important. It helps to project a fair market value of NewAmsterdam Stock properly, considering its historical fundamentals such as Cash And Equivalents. Since NewAmsterdam Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of NewAmsterdam Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of NewAmsterdam Pharma's interrelated accounts and indicators.
Click cells to compare fundamentals
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
In accordance with the recently published financial statements, NewAmsterdam Pharma has 0.0 in Cash And Equivalents. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The cash and equivalents for all United States stocks is 100.0% higher than that of the company.
NewAmsterdam Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses NewAmsterdam Pharma's direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of NewAmsterdam Pharma could also be used in its relative valuation, which is a method of valuing NewAmsterdam Pharma by comparing valuation metrics of similar companies.NewAmsterdam Pharma is currently under evaluation in cash and equivalents category among its peers.
NewAmsterdam Pharma ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, NewAmsterdam Pharma's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to NewAmsterdam Pharma's managers, analysts, and investors.Environmental | Governance | Social |
NewAmsterdam Fundamentals
| Return On Equity | -0.47 | ||||
| Return On Asset | -0.29 | ||||
| Operating Margin | (0.86) % | ||||
| Number Of Shares Shorted | 3.47 K | ||||
| Revenue | 12.76 M | ||||
| EBITDA | (176.86 M) | ||||
| Net Income | (160.27 M) | ||||
| Total Debt | 60 K | ||||
| Book Value Per Share | 4.11 X | ||||
| Cash Flow From Operations | (141.22 M) | ||||
| Number Of Employees | 62 | ||||
| Beta | -0.001 | ||||
| Total Asset | 347.1 M | ||||
| Retained Earnings | (316.97 M) | ||||
| Working Capital | 296.89 M | ||||
| Net Asset | 347.1 M |
About NewAmsterdam Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze NewAmsterdam Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NewAmsterdam Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NewAmsterdam Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for NewAmsterdam Stock Analysis
When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.